Epigenetic Therapy of Cancer

Preclinical Models and Treatment Approaches

  • Michael Lübbert
  • Peter A. Jones

Table of contents

  1. Front Matter
    Pages i-x
  2. Irina Savelyeva, Frank Rosenbauer
    Pages 43-66
  3. Pratima Chaurasia, Dmitriy Berenzon, Ronald Hoffman
    Pages 67-87
  4. Yogen Saunthararajah, Donald Lavelle, Joseph DeSimone
    Pages 89-106
  5. Rainer Claus, Maximilian Schmutz, Gabriele Greve, Lars Bullinger
    Pages 107-120
  6. Jesús Duque-Afonso, Michael Lübbert, Michael L. Cleary
    Pages 121-144
  7. Michael Daskalakis, Tina E. Joeckel, Michael Lübbert, A. Kuendgen
    Pages 145-170
  8. Elizabeth Griffiths, Richard L. Momparler, Adam R. Karpf
    Pages 171-188
  9. Richard Chesworth, Tim J. Wigle, Kevin W. Kuntz, Jesse J. Smith, Victoria M. Richon
    Pages 189-226
  10. Sarah Derks, Manon van Engeland
    Pages 283-298
  11. Robert Brown, Juliane Steinmann, Janet Graham, Ros Glasspool
    Pages 299-317
  12. Back Matter
    Pages 319-325

About this book


The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders such as myeloid leukemias and preleukemias (myelodysplasias) is now being translated into treatment approaches that target the epigenetic defects pharmacologically. Such approaches include reactivation of tumor suppressor genes and other antiproliferative genes by reversal of DNA hypermethylation through azanucleosides, and use of HDAC inhibitors to reverse gene silencing mediated by chimeric, leukemia-specific transcription factors.

This book first presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.


Carcinoma Chromatin DNA Methylation Histone Organisation Myelodysplasia

Editors and affiliations

  • Michael Lübbert
    • 1
  • Peter A. Jones
    • 2
  1. 1.Department of Hematology/OncologyUniversity Medical Center Freiburg, University of FreiburgFreiburgGermany
  2. 2.Norris Comprehensive Cancer Center Urologic Cancer Res. Lab.University of Southern California Dept. Biochemistry & Molecular BiologyLos AngelesUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2014
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Medicine
  • Print ISBN 978-3-642-38403-5
  • Online ISBN 978-3-642-38404-2
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology